Vimta Labs Limited

NSEI:VIMTALABS 주식 보고서

시가총액: ₹19.8b

Vimta Labs 과거 수익 실적

과거 기준 확인 3/6

Vimta Labs은 연평균 27.2%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 증가했으며, 연간 25.2%였습니다. 매출은 연평균 13.7%의 비율로 증가했습니다. Vimta Labs의 자기자본이익률은 14.4%이고 순이익률은 14.6%입니다.

주요 정보

27.2%

수익 성장률

27.1%

EPS 성장률

Life Sciences 산업 성장11.2%
매출 성장률13.7%
자기자본 수익률14.4%
순이익14.6%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Subdued Growth No Barrier To Vimta Labs Limited (NSE:VIMTALABS) With Shares Advancing 28%

Nov 09
Subdued Growth No Barrier To Vimta Labs Limited (NSE:VIMTALABS) With Shares Advancing 28%

There's Reason For Concern Over Vimta Labs Limited's (NSE:VIMTALABS) Massive 31% Price Jump

Sep 06
There's Reason For Concern Over Vimta Labs Limited's (NSE:VIMTALABS) Massive 31% Price Jump

It Looks Like Shareholders Would Probably Approve Vimta Labs Limited's (NSE:VIMTALABS) CEO Compensation Package

Jul 12
It Looks Like Shareholders Would Probably Approve Vimta Labs Limited's (NSE:VIMTALABS) CEO Compensation Package

Vimta Labs (NSE:VIMTALABS) Seems To Use Debt Quite Sensibly

Jun 12
Vimta Labs (NSE:VIMTALABS) Seems To Use Debt Quite Sensibly

Market Might Still Lack Some Conviction On Vimta Labs Limited (NSE:VIMTALABS) Even After 26% Share Price Boost

Apr 26
Market Might Still Lack Some Conviction On Vimta Labs Limited (NSE:VIMTALABS) Even After 26% Share Price Boost

It's A Story Of Risk Vs Reward With Vimta Labs Limited (NSE:VIMTALABS)

Jan 06
It's A Story Of Risk Vs Reward With Vimta Labs Limited (NSE:VIMTALABS)

If EPS Growth Is Important To You, Vimta Labs (NSE:VIMTALABS) Presents An Opportunity

Jul 14
If EPS Growth Is Important To You, Vimta Labs (NSE:VIMTALABS) Presents An Opportunity

Vimta Labs (NSE:VIMTALABS) Has Announced A Dividend Of ₹2.00

Jun 03
Vimta Labs (NSE:VIMTALABS) Has Announced A Dividend Of ₹2.00

Vimta Labs' (NSE:VIMTALABS) Dividend Will Be ₹2.00

May 06
Vimta Labs' (NSE:VIMTALABS) Dividend Will Be ₹2.00

A Look At The Intrinsic Value Of Vimta Labs Limited (NSE:VIMTALABS)

Dec 07
A Look At The Intrinsic Value Of Vimta Labs Limited (NSE:VIMTALABS)

Here's Why We Think Vimta Labs (NSE:VIMTALABS) Might Deserve Your Attention Today

Nov 06
Here's Why We Think Vimta Labs (NSE:VIMTALABS) Might Deserve Your Attention Today

Vimta Labs (NSE:VIMTALABS) Is Due To Pay A Dividend Of ₹2.00

Jun 02
Vimta Labs (NSE:VIMTALABS) Is Due To Pay A Dividend Of ₹2.00

Does Vimta Labs (NSE:VIMTALABS) Deserve A Spot On Your Watchlist?

Dec 06
Does Vimta Labs (NSE:VIMTALABS) Deserve A Spot On Your Watchlist?

Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly

Oct 27
Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Vimta Labs Limited's (NSE:VIMTALABS) CEO For Now

Jun 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Vimta Labs Limited's (NSE:VIMTALABS) CEO For Now

Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?

Jun 19
Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?

Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly

Mar 09
Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly

Vimta Labs Limited's (NSE:VIMTALABS) Stock Is Going Strong: Have Financials A Role To Play?

Jan 20
Vimta Labs Limited's (NSE:VIMTALABS) Stock Is Going Strong: Have Financials A Role To Play?

Did You Miss Vimta Labs' (NSE:VIMTALABS) 87% Share Price Gain?

Dec 30
Did You Miss Vimta Labs' (NSE:VIMTALABS) 87% Share Price Gain?

Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?

Dec 09
Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?

Here's What We Learned About The CEO Pay At Vimta Labs Limited (NSE:VIMTALABS)

Nov 17
Here's What We Learned About The CEO Pay At Vimta Labs Limited (NSE:VIMTALABS)

Vimta Labs Limited's (NSE:VIMTALABS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Oct 21
Vimta Labs Limited's (NSE:VIMTALABS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

수익 및 비용 분석

Vimta Labs 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NSEI:VIMTALABS 수익, 비용 및 수입 (INR Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 243,3764931,0750
30 Jun 243,1764111,0560
31 Mar 243,1934101,0580
31 Dec 233,2124131,0440
30 Sep 233,1694151,0190
30 Jun 233,2344839990
31 Mar 233,1904829800
31 Dec 223,1094739750
30 Sep 223,0094889370
30 Jun 222,9654538790
31 Mar 222,7874138340
31 Dec 212,6443727710
30 Sep 212,5573367380
30 Jun 212,3963147180
31 Mar 212,1102146650
31 Dec 201,9451376370
30 Sep 201,8731046350
30 Jun 201,694375940
31 Mar 201,811686530
31 Dec 191,9141366840
30 Sep 191,9061406730
30 Jun 192,0252006710
31 Mar 192,1302536650
31 Dec 182,1262366660
30 Sep 182,0712456460
30 Jun 181,9702186210
31 Mar 181,8361645950
31 Dec 171,6931345620
30 Sep 171,6021045480
30 Jun 171,552835340
31 Mar 171,5381065030
31 Dec 161,468944600
30 Sep 161,376744330
30 Jun 161,344793490
31 Mar 161,247643820
31 Dec 151,202634860
30 Sep 151,157594750
30 Jun 151,068453160
31 Mar 151,073513430
31 Dec 141,082524770
30 Sep 141,140854660
30 Jun 141,1951144550
31 Mar 141,1831324430
31 Dec 131,1751303950

양질의 수익: VIMTALABS 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: VIMTALABS 의 현재 순이익 이익률 (14.6%) 작년보다 높습니다 (13.1%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: VIMTALABS 의 수익은 지난 5년 동안 매년 27.2% 씩 크게 증가했습니다.

성장 가속화: 지난 1년간 VIMTALABS 의 수익 증가율( 19% )은 5년 평균( 27.2% 보다 낮습니다. 년도).

수익 대 산업: 지난 1년간 VIMTALABS 수익 성장( 19% )은 Life Sciences 업계 37.9% 능가하지 못했습니다. 37.9%.


자기자본 수익률

높은 ROE: VIMTALABS 의 자본 수익률( 14.4% )은 낮음으로 간주됩니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기